George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Regulatory News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.00
Bid: 8.00
Ask: 10.00
Change: -1.00 (-10.00%)
Spread: 2.00 (25.00%)
Open: 9.00
High: 9.00
Low: 8.25
Prev. Close: 10.00
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Redx Pharma Plc

15 Jan 2020 15:17

RNS Number : 9329Z
Sarah Hooker
15 January 2020
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Sarah Hooker

Dennis Hallahane

Paulene Hallahane

Bridget Hallahane

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Redx Pharma Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

N/A

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

14 January 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

1p Ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

2,225,100

1.76

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

2,225,100

1.76

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

15 January 2020

Contact name:

Sarah Hooker

Telephone number*:

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETGPURUGUPUGAA
Date   Source Headline
17th May 20177:00 amRNSInterim results for six months ended 31 March 2017
15th May 20177:00 amRNSPreclinical efficacy data presented on RXC005
4th May 20177:00 amRNSNotice of Interim Results
20th Apr 201711:20 amRNSResult of AGM
20th Apr 20177:00 amRNSAppointment of Chairman
7th Apr 20173:56 pmRNSNotice of Annual General Meeting
3rd Apr 20177:15 amRNSHardman: CARB-X - new strategic collaboration
30th Mar 20174:03 pmRNSRedx Pharma awarded US$1 million grant by CARB-X
21st Mar 20179:05 amRNSFinal Results Year Ended 30 September 2016
7th Mar 20174:33 pmRNSHolding(s) in Company
3rd Mar 20172:35 pmRNSHolding(s) in Company
3rd Mar 20172:27 pmRNSHolding(s) in Company
3rd Mar 20172:17 pmRNSHolding(s) in Company
2nd Mar 20175:01 pmRNSHolding(s) in Company
2nd Mar 20177:50 amRNSRedx presentations at AACR 2017
28th Feb 201710:35 amRNSResult of General Meeting and Issue of Equity
27th Feb 20175:50 pmRNSResult of Open Offer
10th Feb 20171:00 pmRNSResult of Placing
9th Feb 20177:00 amRNSAccelerated Book Build
8th Feb 20176:30 pmRNSAccelerated Book Build
27th Jan 20177:00 amRNSGrowing opportunity for Porcupine inhibitors
6th Dec 20167:00 amRNSReversible BTK poster at ASH meeting
30th Nov 20167:00 amRNSRXC004 pre-clinical profile
16th Nov 20163:22 pmRNSHolding(s) in Company
4th Nov 20167:00 amRNSReversible BTK data at ASH meeting
20th Oct 20167:00 amRNSDevelopment candidate chosen for leukaemia program
11th Oct 20169:32 amRNSExercise of Options and Total Voting Rights
27th Sep 20167:00 amRNSDiscovery of breakthrough antibiotic compounds
23rd Sep 20164:07 pmRNSHolding(s) in Company
21st Sep 20168:50 amRNSHolding(s) in Company
19th Sep 20167:00 amRNSRe: Porcupine inhibitor and cancer immunotherapy
16th Sep 201611:31 amRNSHolding(s) in Company
14th Sep 201610:47 amRNSHolding(s) in Company
8th Sep 20167:00 amRNSBoard & Senior Management Changes
6th Sep 20167:00 amRNSSupply agreement for expected clinical trial
8th Aug 201610:55 amRNSHardman Research: Moving to clinic, rising value
17th Jun 201612:15 pmRNSRedx to present at ASM Microbe 2016 Conference
24th May 20167:00 amRNSProof of concept with key oncology lead
24th May 20167:00 amRNSHalf-year Report
19th May 20167:00 amRNSRe Review on Antimicrobial Resistance
9th May 20167:00 amRNSBoard Appointment
26th Apr 20163:37 pmRNSHolding(s) in Company
19th Apr 20164:52 pmRNSHolding(s) in Company
18th Apr 20167:00 amRNSHolding(s) in Company
15th Apr 20165:10 pmRNSHolding(s) in Company
13th Apr 201612:06 pmRNSResult of General Meeting and Issue of Equity
4th Apr 20162:58 pmRNSGrant of Options
4th Apr 201612:59 pmRNSResult of General Meeting
4th Apr 20167:00 amRNSIssue of Equity
29th Mar 20167:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.